Détail de l'éditeur
Publications Office of the European Union
localisé à :
Luxembourg
|
Documents disponibles chez cet éditeur (111)
Rapport
This report presents the data and findings of the risk assessment on the new psychoactive substance, 4-methylamphetamine, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant drug[...]Rapport
This report presents the data and findings of the risk assessment on the new psychoactive substance, 4-methylamphetamine, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant drug[...]Rapport
This publication presents the data and findings of the risk assessment on N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. I[...]Rapport
This report presents the data and findings of the risk assessment on the new psychoactive substance, 5-(2-aminopropyl)indole, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant [...]Rapport
This publication presents the data and findings of the risk assessment on methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 N[...]Rapport
This publication presents the data and findings of the risk assessment on N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 No[...]Rapport
This publication presents the data and findings of the risk assessment on N-(1 phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 22 February 2017. On the basis of th[...]Rapport
This publication presents the data and findings of the risk assessment on N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7[...]Rapport
Based on the options provided by the international drug control legal framework, this paper considers the rehabilitative measures of treating, educating or reintegrating drug users as alternatives or additions to conviction or punishment that ar[...]Rapport
Europol ; L. LANIEL ; C. CARPENTIER ; J. MOUNTENEY ; B. PALLAVICINI ; L. ROYUELA ; J. MATIAS ; R. KASECKER ; R. SEDEFOV ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Joint publications | 2011FRANÇAIS : L'OEDT et Europol publient une analyse conjointe concernant le marché des amphétamines. Leader dans la production des amphétamines, l'Europe est également une zone importante de consommation. ENGLISH: This joint publication with [...]Rapport
This report presents new findings from the ESCAPE (European Syringe Collection and Analysis Project Enterprise) network, based on the chemical analysis of the contents of used syringes across sentinel sites in Europe. Syringes were collected in [...]Rapport
OEDT = EMCDDA ; A. HEINEMANN ; S. IWERSEN-BERGMANN | Lisbon : OEDT / EMCDDA | Technical reports | 2019The objective of this report is to provide an updated analysis of the post-mortem toxicology practices of drug-related deaths (DRD) in Europe and to discuss the effect of these practices on the monitoring of DRDs. It is based on the results of a[...]Rapport
OEDT = EMCDDA ; S. CASTIGLIONI, Éditeur scientifique ; L. VANDAM ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Insights, ISSN 1606-1683 | 2016"Assessing illicit drugs in wastewater: advances in wastewater-based drug epidemiology" reviews a new approach to estimating drug use in populations, based on the detection and quantification of drugs and their metabolic products in community wa[...]Rapport
This report reviews how opioid substitution treatment (OST) is implemented in European countries and examines the public health consequences of the diversion and misuse of prescription OST medications. It looks at how OST medications are diverte[...]Rapport
Being young in Europe today' presents some of Eurostat's most interesting data on children and young people in the European Union. It gives an insight into the past, current and future situation of our youngest fellow citizens, ranging from atte[...]Rapport
This publication answers some of the more frequently asked questions raised in discussions about cannabis legislation. While the primary focus is on the use of cannabis for recreational purposes, relevant legislation for other uses, including me[...]Rapport
At a time of increased debate on the laws controlling the use of cannabis in the European Union, this report answers some of the questions most often asked about cannabis legislation. Using a question and answer format, basic definitions and the[...]Rapport
OEDT = EMCDDA ; L. LANIEL ; M. GANDILHON ; J. E. ADES ; A. CUNNINGHAM ; N. SINGLETON ; R. SEDEFOV ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2018Captagon is reported to be a commonly used stimulant in the Middle East. In addition, some recent media reports have linked this drug to perpetrators of terrorist acts in Europe or terrorist groups based in areas of conflict in the Middle East. [...]Rapport
This publication presents the data and findings of the risk assessment on methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2[...]Rapport
D. OLSZEWSKI ; G. BURKHART ; A. BO | Lisbon : OEDT / EMCDDA | Thematic Papers, ISSN 1725-5767 | 2010The purpose of this paper is to give meaning and insight into some of the key drug and alcohol issues that affect children from the perspectives of the children themselves. It is not to estimate the relative magnitude of a specific drug or alcoh[...]Rapport
OEDT = EMCDDA ; L. MONTANARI ; M. PASINETTI ; D. THANKI ; J. VICENTE | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2013Identifying the co-occurrence of drug use and mental health disorders in the same individuals is essential for effective treatment of their drug use problems. Reviewing the available information on psychiatric co-morbidity among drug users in Eu[...]Rapport
Community coalitions are a strategy to coordinate activities and resources to prevent adolescent substance use and delinquent behaviour. They can help mobilise communities in prevention and health promotion initiatives. The Communities That Car[...]Rapport
OEDT = EMCDDA ; M. TORRENS ; J. I. MESTRE-PINTO ; A. DOMINGO-SALVANY ; L. MONTANARI ; J. VICENTE | Lisbon : OEDT / EMCDDA | Insights, ISSN 1606-1683 | 2015This publication looks at the co-occurrence of drug use problems and mental health disorders, taking in the theoretical background of psychiatric comorbidity, the tools for clinical diagnosis and the prevalence and clinical relevance of the prob[...]Rapport
This publication presents the data and findings of the risk assessment on 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017.[...]Rapport
This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 21 March 2018.[...]Rapport
This paper presents the EMCDDA's current thinking on the conceptual framework for monitoring drug markets, crime and supply reduction - building on the work completed in this area and expanding to reflect the academic research underpinning this [...]Rapport
OEDT = EMCDDA ; T. FREEMAN ; T. GROSHKOVA ; A. CUNNINGHAM ; P. GRIFFITHS ; D. POTTER ; S. CRAFT ; A. ENGLUND ; M. LYNSKEY ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2019ENGLISH: This paper provides an overview of established and emerging cannabis products in Europe. For each type of product, major issues in its production, distribution, use and effects on health are detailed. In doing so, the paper seeks to in[...]Rapport
OEDT = EMCDDA ; H. SCHULZE, Coordonnateur ; M. SCHUMACHER ; R. URMEEW ; K. AUERBACH ; J. ALVAREZ ; I. M. BERNHOFT ; H. DE GIER ; M. HAGENZIEKER ; S. HOUWING ; A. KNOCHE ; B. PILGERSTORFER ; B. ZLENDER ; B. HUGHES ; L. VANDAM | Lisbon : OEDT / EMCDDA | Thematic Papers, ISSN 1725-5767 | 2012This Thematic paper presents the key findings of the European Union’s research project on Driving Under the Influence of Drugs, Alcohol and Medicines, known as the DRUID project. The project looked at experimental studies, epidemiological studie[...]Rapport
FRANÇAIS : Les peines prononcées à l'encontre des délinquants pour des infractions liées à la drogue à travers l'Union européenne sont examinées pour la première fois dans la présente «Question spécifique». En analysant les statistiques les pl[...]Rapport
OEDT = EMCDDA ; A. O'GORMAN ; E. QUIGLEY ; F. ZOBEL ; K. MOORE | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2013This study explores the civil society organisations that engage in drug policy advocacy in Europe. An Internet search in English, French and Spanish combined with information from national sources in 30 countries identified 218 organisations act[...]Rapport
This paper describes the development and main characteristics of drug policy in Austria. It traces the development of Austrian drug laws from the time of the Austro-Hungarian Empire through to the present day. Austria's drug policy has several d[...]Rapport
This paper describes the development and main characteristics of drug policy in Poland. It starts with the early days of drug control in Poland in the 1920s, describes the changes related to the emergence of Polish heroin - Kompot - in the late [...]Rapport
OEDT = EMCDDA ; E. QUIGLEY ; B. HUGHES ; C. COSTA STORTI ; F. ZOBEL | Lisbon : OEDT / EMCDDA | Drug policy profiles, ISSN 1977-2246 | 2013The national drug policy of Ireland comes under the spotlight in the second volume in the EMCDDA series of Drug policy profiles. Examining the evolution of Irish drug policy through four periods of historic development, the report explores: the [...]Rapport
This paper describes the significant developments that have occurred in the last 5 to 10 years in the field of drug precursors related to synthetic stimulant drugs produced in the EU. This includes describing the 'pre-precursor' phenomenon and r[...]Rapport
This report considers substance use prevention in Europe through the lens of a system, highlighting the wide range of factors that need to be addressed to successfully implement substance use prevention programmes and policies. They are consider[...]Rapport
This publication provides an update on drug-related deaths in Europe, presenting and analysing the latest data and trends in drug-induced deaths and overall mortality among high-risk drug users in the European Union and beyond. It draws on contr[...]Rapport
OEDT = EMCDDA ; I. GIRAUDON ; F. MATHIS ; D. HEDRICH ; J. VICENTE ; A. NOOR | Lisbon : OEDT / EMCDDA | Technical reports | 2021This report provides an update on drug-related deaths in Europe based primarily on presentations and discussions held at the 2019 meeting of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) expert network on drug-related deat[...]Rapport
This report is part of the EMCDDA activity around the development and improvement of drug supply indicators, which are designed to reflect developments in drug markets as well as the markets' wider harms and impact. The protocol in this document[...]Rapport
Homicide is a violent act that generates high social costs. In particular, drug-related homicide (DRH) has the potential to act as an indicator of wider drug-related crime. Comparing DRH levels between countries with data on this topic can be a [...]Rapport
OEDT = EMCDDA ; I. GIRAUDON ; A. M. DINES ; N. SINGLETON ; A. NOOR ; P. I. DARGAN ; D. WOOD | Lisbon : OEDT / EMCDDA | Technical reports | 2020ENGLISH: This report presents the latest findings on drug-related hospital emergencies from a network of sentinel hospitals across Europe. Almost 24 000 emergency presentations were recorded at 32 sentinel hospitals over the first 4 years of th[...]Rapport
This 2020 EMCDDA update on drug-related infectious diseases aims to provide a comprehensive overview of the current situation with regard to the epidemiological picture of drug-related infectious diseases in Europe up to January 2020, while high[...]Rapport
This report presents an overview of infectious diseases among people who inject drugs in Europe, both in the community and in prison settings, covering disease surveillance, outbreak investigations, and prevention and control, for the period up [...]Rapport
This report provides an update on infectious diseases related to injecting drug use in Europe. It covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area. The report [...]Rapport
This report provides an update on infectious diseases related to injecting drug use in Europe. It covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area. The report [...]Rapport
This report provides an update on infectious diseases related to injecting drug use in Europe for the period up to June 2015. The report covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and[...]Rapport
OEDT = EMCDDA ; L. LANIEL ; R. KASECKER ; T. GROSHKOVA ; C. CARPENTIER | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2013Drug law enforcement activity targets the supply of drugs and is responsible for much of the key data that informs our understanding of drugs supply in Europe. This study looks, for the first time, at how drug law enforcement is organised in Eur[...]Rapport
OEDT = EMCDDA ; L. LANIEL ; T. SURMONT ; T. STOIAN ; S. ALM | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2017In 2014, the EMCDDA took the decision to carry out a limited follow-up study of the EMCDDA Paper Drug squads: units specialised in drug law enforcement in Europe (EMCDDA, 2013), with the aim of monitoring possible changes and trends in drug supp[...]Rapport
OEDT = EMCDDA ; E. QUIGLEY ; R. SEDEFOV ; C. CARPENTIER ; L. LANIEL ; European Commission, COWI Consortium for DG Health and Consumers | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2013The production and trafficking of illicit drugs poses complex and interlinked problems, which have a negative impact on public health and the security and stability of society. Focusing on actions directed at the EU's internal security situation[...]Rapport
It is estimated that over 1 million people receive treatment for drug-related problems in the European Union every year. With shrinking public budgets, increasing pressure on health systems, changes in the drugs used and the need to provide on-g[...]Rapport
This report presents a summary of the key findings from drug treatment facility surveys carried out in 2017 in Albania, Bosnia and Herzegovina, Serbia and the territory of Kosovo. The results provide insight into the characteristics and capacity[...]